Senseonics Holdings Inc. (AMEX:SENS) saw its stock surge 5.13% in after-hours trading on Tuesday, following the release of impressive preliminary third-quarter results and the announcement of a reverse stock split. This positive movement comes as a stark contrast to the stock's performance during regular trading hours, where it had fallen 17.5%.

The diabetes care technology company reported preliminary Q3 FY25 revenue of approximately $8.1 million, surpassing the consensus estimate of $7.8 million. This represents a substantial 91% year-over-year increase, driven by remarkable growth in new U.S. patients. Senseonics also recorded its highest-ever monthly new patient starts in September 2025, showcasing the growing adoption of its Eversense continuous glucose monitoring system.

Adding to the news, Senseonics announced a one-for-twenty reverse stock split, set to take effect on October 17, 2025. This move will reduce the total outstanding shares from approximately 816 million to roughly 41 million. The company's CEO, Tim Goodnow, expressed confidence in their ability to drive top-line revenue growth, citing the success of their direct-to-consumer marketing campaigns. With the recent decision to bring the full sales and marketing organization in-house, Senseonics appears poised for continued growth in the competitive diabetes care market.